fda glp-1 warning 2025 november The has received hundreds of adverse event reports tied to compounded GLP-1s. PRI's brief warns that patients should know the risks before trusting knockoff versions. Read the brief: https://medecon.org/unauthorized-glp-1-knockoffs/ FDA Issues Warning Letters to

In contrast, no benefits on the rate of decline in glomerular filtration rate have been seen in trials of DPP-4 inhibitors, perhaps because the renal actions of DPP-4 inhibitors are primarily mediated by potentiation of SDF-1, not GLP-1

BEHIND THE HYPE-- GLP-1 MEDS: We spent months digging into the benefits and costs involving GLP-1 medications

Don't tell me about it, invite me!

While weight loss itself often improves anxiety symptoms, emerging research suggests the medication may have direct effects on stress pathways independent of body composition changes

10% off your first order

When branded therapies of semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) commanded high prices and faced prolonged shortages from late 2022 through early 2025, compounding pharmacies emerged as alternative providers offering lower-cost formulations